A practical reference on nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
== External links == David Hawgood, One-Place Genealogy, Hawgood, 2001 ^ Society for One-Place Studies - worldwide society for individuals and groups interested in studying one-place family and/or local history
The association with celiac disease is unclear, with a 2019 study finding no increase in dementia overall in those with celiac disease, while a 2018 review found an association with several types of dementia, including Alzheimer's disease. Some studies have reported a potential link between infection with certain viruses and developing Alzheimer's disease later in life, such as COVID-19 or Herpes simplex virus 1 (HSV-1). Some researchers have proposed that Alzheimer's disease is type 3 diabetes because of a number of correspondences with both type 1 and type 2 diabetes.
== Academic and professional career == In 1982, Wu began his academic career as assistant professor of Pathology and Laboratory Medicine at the University of Texas Health Science Center in Houston, where he served as Associate and then Director of Clinical Chemistry at Memorial Hermann Hospital. After a decade in Texas, Wu left for a position at Hartford Hospital, where he served as Director of Clinical Chemistry and Professor of Laboratory Medicine at the University of Connecticut Health Center. He also held appointments as Professor of Pathobiology and Chemistry at the University of Connecticut, Storrs. In 2004, Wu joined the faculty at the University of California, San Francisco as Professor of Laboratory Medicine and Director of Clinical Chemistry, Toxicology, and Pharmacogenomics at San Francisco General Hospital.
== American football scandals == Boat Party (2005) – a sex party involving several members of the Minnesota Vikings of the National Football League (NFL) National Football League player conduct controversy (2007–present) – various off the field incidents involving American football athletes from the NFL, including Adam "Pacman" Jones, Terry "Tank" Johnson, Chris Henry, Ben Roethlisberger, Ray Rice, Deshaun Watson, and Adrian Peterson, who earned suspensions as a result. 2007 New England Patriots videotaping controversy (2007) – the New England Patriots were disciplined for videotaping the opposing team's coach's signals. Coach Bill Belichick was fined $500,000 and the New England Patriots were fined $250,000 and lost their 2008 1st-round draft pick. New Orleans Saints bounty scandal (2012) – the NFL discovered that the New Orleans Saints had operated a secret slush fund from 2009 to 2011 that paid "bounties" to defensive players for big plays during games, most controversially for injuring opponents. The scheme was allegedly organized by a number of players plus defensive coordinator Gregg Williams, with the acquiescence of head coach Sean Payton. Shortly after the investigation came to light, Williams was accused of running similar schemes while he was defensive coordinator of the Houston Oilers/Tennessee Titans and Washington Redskins, as well as the head coach of the Buffalo Bills. The league suspended Williams indefinitely and Payton for one year and suspended the Saints' general manager and another assistant for parts of the 2012 season.
Sources: en.wikipedia.org
Morpholino nucleic acids replace the sugar with a morpholine component, and the phosphate with a phosphorodiamidate component. Miravirsen is an antisense drug candidate that incorporates both locked nucleic acid sugar components and phosphorothioate groups.
The therapsid lineage leading to mammals went through a series of stages, beginning with animals that were very similar to their early synapsid ancestors and ending with probainognathian cynodonts, some of which could easily be mistaken for mammals. Those stages were characterized by:
=== Host immune response === Fibroblasts from different anatomical sites in the body express many genes that code for immune mediators and proteins. These mediators of immune response enable the cellular communication with hematopoietic immune cells. The immune activity of non-hematopoietic cells, such as fibroblasts, is referred to as "structural immunity". In order to facilitate a fast response to immunological challenges, fibroblasts encode crucial aspects of the structural cell immune response in the epigenome.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.